New in @NEJM and #AACR2025: Our Early-stage MMR-d neoadj I/O trial (led by @AndreaCercek & Luis Diaz)
•100 % cCR in 49 rectal pts
•65 % cCR across 10 other cancers (n=54)
•Safe + all non-CR/recurs salvaged.
=Use IO in NA for MMR-d tumors!
https://t.co/p6z3Q90ZTw
After almost 2 years of work, I'm beyond thrilled to share TESSERA 🎉
🧬 A foundation model for the cancer genome.
One genomic fingerprint →
🩺 Diagnosis
📈 Prognosis
🧪 Prediction
🚀 Preprint LIVE → https://t.co/BK2iZMbj8C
#CancerGenomics#FoundationModels#AIinMedicine
We are thrilled to share our latest work out today @Dev_Cell! Appendiceal adenocarcinoma (AC) is a rare, aggressive cancer that frequently spreads to the peritoneum. Until now, lack of robust preclinical models has severely limited drug discovery. https://t.co/8rPe1G87CZ🧵👇 🔗
@acpmpresearch@mskcc Thank you so much to the ACPMP and supporters for this great honor! We can’t wait to get started on finding new treatments for our patients.
We are proud to announce @MikeFooteMD of @MSKCC as the first-ever recipient of our $150K ACPMP Changemaker Research Grant for his research project, “Targeting the Surface Proteome of Appendiceal Cancer Peritoneal Metastasis.”
This research is made possible by our donors!🎗️
Big day for a rare disease 🎉🧬
The new NCCN Guidelines for Appendiceal Cancer just dropped — and they’re fantastic. For the first time, this rare and often misunderstood disease finally gets its own dedicated guidance, instead of the old “just follow colorectal cancer” footnote.
📘 Clear frameworks for diagnosis, staging, and management
🔍 Recognition that appendiceal primaries are biologically distinct
💡 Emphasis on multidisciplinary care and the need for more trials
Only downside? @jpshen_md and Michael Foote — two of the biggest names in this space — weren’t listed as contributors.
Still, a huge step forward for patients and clinicians who’ve long been navigating in the dark. The field is finally getting the structure it deserves.
https://t.co/10MLAkG1Mi
@OncoAlert@TheGutOncLab #GIOncology #AppendicealCancer @acpmpresearch
Exciting research is ahead at #ESMO25! Tomorrow, @MikeFooteMD will present interim safety and efficacy data of a phase 1/1b study of an investigational drug for people with advanced solid tumors. @MSKCancerCenter@myESMO
Learn more: https://t.co/6ZhqtdZfN0
Very excited about our work with 60+ collaborators across the world to define algorithms for management of patients with peritoneal disease! https://t.co/CppEQ8gbWg
Part 1: Consensus guideline for the management of patients with appendiceal tumors: Appendiceal tumors without peritoneal involvement - Godfrey - 2025 - Cancer - Wiley Online Library https://t.co/dYjTLYSeSa @DeepaMagge@kturaga@ArdamanShergil1@MikeFooteMD@JournalCancer@appendix #cancer #raretumors
🚨 New research from @ASCO: A clinical trial led by @YJanjigianMD, Chief of Gastrointestinal Medical Oncology at MSK, has demonstrated a powerful new approach to help prevent cancer from coming back after treatment for #stomachcancer and #cancer of the lower portion of the #esophagus and gastroesophageal junction (#GEJ).
“For gastroesophageal cancer patients to go through surgery and chemo, it’s devastating to have a recurrence of the cancer,” says Dr. Janjigian. “This trial shows that adding immunotherapy to chemo before and after surgery can dramatically improve the chance that cancer won’t return.”
Learn more about how these results offer new hope to people facing this diagnosis, which is the fifth most common cancer worldwide: https://t.co/C4hzxgoabS
#ASCO25
Congratulations to our team. Next chapter in Nonoperative Management of Mismatch Repair–Deficient Tumors | New England Journal of Medicine https://t.co/HSiWCtCiSz
New paper from our team at @MSKCancerCenter. Nonoperative Management of Mismatch Repair–Deficient Tumors | New England Journal of Medicine https://t.co/H9bnB54BFf
Presented at #AACR25:
Neoadjuvant PD-1 blockade with dostarlimab led to organ preservation in a high proportion of patients with early-stage mismatch repair–deficient tumors, with no compromise of surgical options. Full study results: https://t.co/o5tjgLnXm6
@AACR
An approach pioneered at MSK that caused #rectalcancer tumors with a specific genetic mutation to disappear in 100% of clinical trial participants has been expanded to treat other types of cancer, including stomach (gastric), colon, esophageal, urothelial, and others.
Gastrointestinal oncologist @AndreaCercek presented the results from a larger clinical trial at #AACR25. The new results saw 80% of patients with several types of cancer successfully treated with only #immunotherapy.
“This is very exciting and shows that a broad range of tumors with this genetic mutation called MMRd can be treated with immunotherapy replacing surgery and radiation, giving patients better quality of life." Learn more: https://t.co/RoAJIHtizP #AACR25 @AACR